For laboratory research only.

Everything sold on peptidesth.com is supplied for in-vitro research and laboratory use. These materials are not drugs, supplements, or food. They are not intended for human or animal consumption, diagnostic use, or therapeutic use.

Please confirm you are 21 or older before continuing. Our research desk ships from Bangkok to qualified buyers in Thailand and worldwide.

Your acknowledgement is remembered on this device for 24 hours.

You’re about to view data for this compound.

This compound is supplied strictly for in-vitro research. It is not a medicine and is not intended for human or animal use. By continuing, you confirm you are 21 or older and accessing this information for laboratory purposes.
Thailand Peptides
Get in Contact
CompareGH Secretagogue

CJC-1295 vs CJC-1295 DAC

CJC-1295 with DAC and CJC-1295 without DAC are the same GHRH(1-29) analog separated by a single engineering decision — whether to attach the drug affinity complex (DAC) maleimide group that binds plasma albumin. That one addition changes half-life from roughly thirty minutes to roughly eight days and reshapes the entire research protocol around the molecule.

Bangkok research desk ·

Side-by-side

CJC-1295 CJC-1295 DAC
MechanismModified GHRH(1-29); short plasma half-life; pulsatile GH release on each dose.Modified GHRH(1-29) plus DAC maleimide; albumin-bound; sustained GHRH tone across the week.
Half-life~30 minutes.~8 days.
Dose100-200 mcg × 2-3 daily SC (mimics endogenous pulsatility).1-2 mg weekly SC (single weekly injection).
Cycle12 weeks on / 4 off.12 weeks on / 4 off.
Research contextPulsatile preservation of physiological GH-IGF-1 rhythm; commonly co-administered with Ipamorelin2.Sustained elevation of basal IGF-1 across ~8-day half-life in human volunteers1.
Cost tierMid (low per-mg, but 6-21 doses per week).High (premium per-mg, single weekly dose offsets).

CJC-1295 (No DAC) and CJC-1295 with DAC are functionally the same GHRH(1-29) sequence — the difference is the drug-affinity-complex (DAC) maleimide group covalently linked to the peptide. DAC binds albumin in plasma and extends the half-life from approximately thirty minutes to approximately eight days1. Every other property — receptor affinity, mechanism of action, GH-IGF-1 axis engagement — is shared between the two variants.

The half-life difference is the entire research-protocol decision. CJC-1295 No DAC produces a short pulse of GHRH activity, which the pituitary responds to with a corresponding GH pulse. This mimics endogenous pulsatility and is the variant typically paired with a GHS-R1a agonist like Ipamorelin for stack research2. It requires multiple subcutaneous injections per day (typically two to three) to maintain stable GH stimulation. CJC-1295 with DAC produces a sustained elevation of circulating GHRH tone, which raises baseline IGF-1 across the week. Researchers studying body-composition or sustained IGF-1 endpoints select DAC for the dosing economy; researchers studying GH pulsatility or natural rhythm select No DAC.

Cost and convenience pull in opposite directions. CJC-1295 with DAC is more expensive per milligram but requires one injection per week; CJC-1295 No DAC is cheaper per milligram but requires six to twenty-one injections per week depending on the protocol. The weekly-dose protocol is the more common research-setting choice when the endpoint does not specifically require pulsatility. See Ipamorelin vs CJC-1295 mechanism deep-dive for the pulsatile-stack context and GH secretagogue cycle design for full protocol design.

Frequently asked

What does the DAC modification actually do?
The drug affinity complex (DAC) is a maleimide group attached to the peptide that covalently binds circulating albumin. Albumin-bound peptide is cleared much more slowly than free peptide, which extends the plasma half-life from ~30 minutes (No DAC) to ~8 days (with DAC).
Which variant should I use for a GH stack with Ipamorelin?
The pulsatile-mimicry research tradition uses CJC-1295 No DAC alongside Ipamorelin, with both compounds dosed multiple times daily. The combination preserves endogenous pulsatility better than DAC plus Ipamorelin because the No-DAC variant matches the short-pulse pharmacology of Ipamorelin2.
Is the DAC variant safer or stronger?
Neither stronger nor weaker — same receptor binding and same GH-release mechanism. The DAC variant is "different in profile," not "more potent." Safety profiles are comparable in the limited research data; both are research compounds, not clinically registered therapies.
Why is CJC-1295 No DAC cheaper if the molecule is similar?
The DAC maleimide adds synthesis steps and increases the manufacturing complexity. The added molecular weight and engineering cost is the source of the price premium for the DAC variant.
Research desk
Ordering both CJC-1295 and CJC-1295 DAC for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID: 16352683
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822

All references verified against PubMed via NCBI E-utilities.